Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma

@article{Thomas2016ImmuneMA,
  title={Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma},
  author={Alissa A Thomas and Jan L. Fisher and Thomas H. Hampton and Brock C. Christensen and Gregory J. Tsongalis and Gilbert J Rahme and Chery A. Whipple and Sandra E. Steel and Melissa C. Davis and Arti B. Gaur and Lionel D. Lewis and Marc S. Ernstoff and Camilo E. Fadul},
  journal={Cancer Immunology, Immunotherapy},
  year={2016},
  volume={66},
  pages={379-389}
}
Vascular endothelial growth factor (VEGF), in addition to being pro-angiogenic, is an immunomodulatory cytokine systemically and in the tumor microenvironment. We previously reported the immunomodulatory effects of radiation and temozolomide (TMZ) in newly diagnosed glioblastoma. This study aimed to assess changes in peripheral blood mononuclear cell (PBMC) populations, plasma cytokines, and growth factor concentrations following treatment with radiation, TMZ, and bevacizumab (BEV). Eleven… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Similar Papers

Loading similar papers…